Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413790 · ClinicalTrials.gov registry record · Phase 4
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 162
- Enrollment target
NCT00413790 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 162 participants.
The verdict
NCT00413790, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 162 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older
Interventions
- DRUG Placebo
- DRUG Tolterodine
- DRUG Darifenacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413790
The ClinicalTrials.gov registry entry for NCT00413790 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00413790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413790 about?
NCT00413790 is a clinical study titled "Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects". This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older
What is the current status of trial NCT00413790?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 162 participants. The study started on 2006-11. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00413790?
The interventions under investigation include: Placebo (DRUG), Tolterodine (DRUG), Darifenacin (DRUG).
Who is sponsoring clinical trial NCT00413790?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.